Shots:

• Bayer enters into an agreement with PHRI to launch a clinical research program with an aim to identify the potential treatment for COVID-19. The research program includes two studies that evaluate different combination therapies including Bayer’s chloroquine and interferon beta-1b
• Bayer will provide its therapies and will fund $1.08M towards the studies which added to $0.35 funded by PHRI earlier this month- enabling the development of the research program. PHRI intend to enroll 6-000 patients in the two studies from 60+ research sites across the Canadian province of Ontario and internationally
• The first study will assess the combination of chloroquine + azithromycin to test whether it can prevent deterioration leading to hospital admission- while a second study will evaluate the combination of chloroquine + azithromycin + interferon beta-1b to prevent admission to intensive care- mechanical ventilation and death to combat COVID-19

Click here ­to­ read full press release/ article | Ref: Bayer | Image: Latifundist